Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 4
1980 2
1981 1
1982 2
1983 2
1984 4
1985 1
1986 4
1987 1
1988 8
1989 2
1990 1
1991 5
1992 4
1993 6
1994 9
1995 11
1996 11
1997 18
1998 20
1999 18
2000 12
2001 8
2002 11
2003 13
2004 17
2005 11
2006 10
2007 7
2008 10
2009 9
2010 12
2011 12
2012 10
2013 8
2014 15
2015 10
2016 10
2017 12
2018 5
2019 7
2020 11
2021 12
2022 11
2023 6
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Results by year

Filters applied: . Clear all
Page 1
A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
Wang W, Ning G, Ma J, Liu X, Zheng S, Wu F, Xu L, O'Neill EA, Fujita KP, Engel SS, Kaufman KD, Shankar RR. Wang W, et al. Curr Med Res Opin. 2017 Apr;33(4):693-699. doi: 10.1080/03007995.2016.1277200. Epub 2017 Jan 25. Curr Med Res Opin. 2017. PMID: 28035868 Clinical Trial.
OBJECTIVE: To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on acarbose monotherapy. RESEARCH DESIGN AND METHODS: This was a multicenter, randomized, placebo-cont …
OBJECTIVE: To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus (T2DM) a …
Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus myo-inositol in ameliorating the metabolic and endocrinologic complications of polycystic ovary syndrome - A randomized controlled trial.
Andavar M, Kamaraj R, Mahalingam Vijayakumar T, Murugesan A. Andavar M, et al. Eur J Obstet Gynecol Reprod Biol. 2024 Sep;300:6-11. doi: 10.1016/j.ejogrb.2024.07.001. Epub 2024 Jul 3. Eur J Obstet Gynecol Reprod Biol. 2024. PMID: 38972164 Clinical Trial.
AIM: The aim of the study is to determine and compare the effectiveness of acarbose plus metformin and acarbose plus myo-inositol combination therapy in alleviating the metabolic and endocrinologic complications of PCOS. ...Increase in serum progesterone and reducti …
AIM: The aim of the study is to determine and compare the effectiveness of acarbose plus metformin and acarbose plus myo-inosi …
Evaluation of the Bioequivalence of Acarbose in Healthy Chinese People.
Chen Y, Guo F, Wang X, Liu L, Yang C, Xiong Y, Zhang H. Chen Y, et al. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1225-1230. doi: 10.1002/cpdd.921. Epub 2021 Feb 19. Clin Pharmacol Drug Dev. 2021. PMID: 33606918 Free PMC article. Clinical Trial.
Two clinical trials with acarbose were conducted: study A, a pilot study (n = 12; 50 and 100 mg), and study B, a pivotal study (n = 60; 50 mg). In study A, there was a dose-dependent relationship between 50 mg acarbose and 100 mg acarbose and a significant di …
Two clinical trials with acarbose were conducted: study A, a pilot study (n = 12; 50 and 100 mg), and study B, a pivotal study (n = 6 …
Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Cheng H, Zhang Z, Zhang B, Zhang W, Wang J, Ni W, Miao Y, Liu J, Bi Y. Cheng H, et al. Diabetes Care. 2022 May 1;45(5):1201-1210. doi: 10.2337/dc21-2064. Diabetes Care. 2022. PMID: 35263425 Clinical Trial.
Here, we investigated the therapeutic effects of liraglutide, dapagliflozin, or acarbose treatment on brain functional alterations and cognitive changes in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Thirty-six patients with type 2 diabetes inadequately con …
Here, we investigated the therapeutic effects of liraglutide, dapagliflozin, or acarbose treatment on brain functional alterations an …
Acarbose bioequivalence: Exploration of eligible protocol design.
Que L, Huang K, Ding Y, Chu N, Yang J, Qian Z, He Q. Que L, et al. J Clin Pharm Ther. 2021 Apr;46(2):492-503. doi: 10.1111/jcpt.13313. Epub 2020 Dec 16. J Clin Pharm Ther. 2021. PMID: 33325562 Clinical Trial.
WHAT IS KNOWN AND OBJECTIVE: Acarbose is a poorly absorbed alpha-glucosidase inhibitor that acts locally in the intestinal tract. ...Study 1 aimed to determine appropriate dosing time by comparing the PD effect of acarbose between two administration methods. One met …
WHAT IS KNOWN AND OBJECTIVE: Acarbose is a poorly absorbed alpha-glucosidase inhibitor that acts locally in the intestinal tract. ... …
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.
Dewan P, Shen L, Pedro Ferreira J, Jhund PS, Anand IS, Chandra A, Chiang LM, Claggett B, Desai AS, Gong J, Lam CSP, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Solomon SD, McMurray JJV. Dewan P, et al. Circulation. 2024 Jul 23;150(4):272-282. doi: 10.1161/CIRCULATIONAHA.124.068774. Epub 2024 Jun 6. Circulation. 2024. PMID: 38841854 Free article. Clinical Trial.
The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24).
Zhang XL, Yuan SY, Wan G, Yuan MX, Yang GR, Fu HJ, Zhu LX, Zhang JD, Li YL, Gao DY, Cui XL, Wang ZM, Xie RR, Chen YJ. Zhang XL, et al. Sci Rep. 2021 Mar 1;11(1):4839. doi: 10.1038/s41598-021-84015-0. Sci Rep. 2021. PMID: 33649485 Free PMC article. Clinical Trial.
All patients were followed-up to assess the long-term effects of the multifactorial interventions. At baseline, compared with the acarbose therapy free in T2DM, there was no significant difference in achieving the joint target control in patients with acarbose thera …
All patients were followed-up to assess the long-term effects of the multifactorial interventions. At baseline, compared with the acarbos
Oral glucose sensing in cephalic phase insulin release.
Pullicin AJ, Wils D, Lim J. Pullicin AJ, et al. Appetite. 2023 Dec 1;191:107070. doi: 10.1016/j.appet.2023.107070. Epub 2023 Oct 1. Appetite. 2023. PMID: 37788735 Free article. Clinical Trial.
Four stimulus conditions possessing different carbohydrate and taste profiles were designed: 1) glucose alone; 2) glucose mixed with lactisole, a sweet taste inhibitor; 3) maltodextrin, which is digested to starchy- and sweet-tasting products during oral processing; and 4) maltod …
Four stimulus conditions possessing different carbohydrate and taste profiles were designed: 1) glucose alone; 2) glucose mixed with lactiso …
Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
Clissold SP, Edwards C. Clissold SP, et al. Drugs. 1988 Mar;35(3):214-43. doi: 10.2165/00003495-198835030-00003. Drugs. 1988. PMID: 3286212 Review.
In comparative studies acarbose was significantly superior to placebo, and comparable to biguanides, when used alone or as an adjuvant to sulphonylurea therapy. ...The incidence of these reactions usually decreases with time. Thus, acarbose represents the first of a …
In comparative studies acarbose was significantly superior to placebo, and comparable to biguanides, when used alone or as an adjuvan …
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF. Derosa G, et al. Curr Med Res Opin. 2009 Mar;25(3):607-15. doi: 10.1185/03007990802711024. Curr Med Res Opin. 2009. PMID: 19232035 Clinical Trial.
OBJECTIVE: To compare the metabolic effects of acarbose and repaglinide in type 2 diabetic patients who are being treated with a sulphonylurea-metformin combination therapy. ...RESULTS: Seven patients did not complete the study, comprising one patient who was lost to follo …
OBJECTIVE: To compare the metabolic effects of acarbose and repaglinide in type 2 diabetic patients who are being treated with a sulp …
368 results